🔎 Trials Near Me

Domov › Rak jajčnikov › Ohio › Columbus

Klinične študije za Rak jajčnikov v Columbus, OH

39 študij za Rak jajčnikov išče udeležence na lokacijah v Columbus in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Vključevanje udeležencevFaza 2/3
  • Ohio State University Comprehensive Cancer Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Vključevanje udeležencevFaza 2
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • in še 13
Vse starosti · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT05564377

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Vključevanje udeležencevFaza 1/2
  • Research Site, Columbus
Starost 18–130 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT05797168

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Vključevanje udeležencevFaza 2
  • Site 0243 - Mark H Zangmeister Cancer Center, Columbus
  • Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi stran
Starost 18 in več · Ženske · Posodobljeno 29. sep. 2026 · NCT05128825

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Vključevanje udeležencevOpazovalna študija
  • The Ohio State University Comprehensive Cancer Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT04981119

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Vključevanje udeležencevFaza 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Starost 18 in več · Ženske · Posodobljeno 25. sep. 2026 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Vključevanje udeležencevFaza 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Starost 18 in več · Ženske · Posodobljeno 24. sep. 2026 · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Vključevanje udeležencevFaza 2
  • Research Site, Columbus
Starost 18–130 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT05489211

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Vključevanje udeležencevFaza 3
  • The Mark H Zangmeister Center, Columbus
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Hilliard · 10 mi stran
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07213804

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Vključevanje udeležencevFaza 2
  • Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard · 10 mi stran
Starost 18 in več · Ženske · Posodobljeno 22. sep. 2026 · NCT07059845

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Vključevanje udeležencevFaza 3
  • Ohio Health Research Institute, Columbus
Starost 18 in več · Ženske · Posodobljeno 15. sep. 2026 · NCT07214779

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Vključevanje udeležencevFaza 2
  • The Mark H Zangmeister Cancer Center Ohio, Columbus
  • The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard · 10 mi stran
Starost 18–99 · Ženske · Posodobljeno 15. sep. 2026 · NCT07023627

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Vključevanje udeležencevFaza 2
  • The Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi stran
Starost 18 in več · Ženske · Posodobljeno 14. sep. 2026 · NCT06787612

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Vključevanje udeležencevFaza 1/2
  • Ohio State University, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06303505

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Vključevanje udeležencevFaza 1
  • The Ohio State University (OSU) Wexner Medical Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT06400472

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Vključevanje udeležencevFaza 3
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Starost 18 in več · Ženske · Posodobljeno 3. sep. 2026 · NCT06824467

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Vključevanje udeležencevFaza 3
  • OhioHealth Research Institute, Columbus
Starost 18 in več · Ženske · Posodobljeno 26. avg. 2026 · NCT05281471

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Vključevanje udeležencevFaza 1
  • The Ohio State University, Columbus
Starost 15 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT06276491

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Vključevanje udeležencevFaza 1
  • Ohio State University Wexner Medical Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT07470853

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Vključevanje udeležencevZgodnja faza 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Starost 18 in več · Ženske · Posodobljeno 17. avg. 2026 · NCT07144826

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Vključevanje udeležencevFaza 1/2
  • The Ohio State University, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 13. avg. 2026 · NCT05985655

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Vključevanje udeležencev
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • Riverside Methodist Hospital, Columbus
  • in še 8
Starost 35–50 · Ženske · Posodobljeno 7. avg. 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Vključevanje udeležencevFaza 3
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • Riverside Methodist Hospital, Columbus
  • in še 8
Starost 18 in več · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06580314

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Vključevanje udeležencevFaza 1/2
  • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT05579366

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Vključevanje udeležencevFaza 2/3
  • Ohio State University Wexner Medical Center, Hilliard · 10 mi stran
Starost 18 in več · Vsi spoli · Posodobljeno 28. jul. 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Vključevanje udeležencevFaza 2
  • The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Starost 8 in več · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT05503797

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Vključevanje udeležencevFaza 2
  • Ohio State University, Columbus
Starost 18 in več · Ženske · Posodobljeno 14. jul. 2026 · NCT04606914

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Vključevanje udeležencevFaza 1/2
  • Stefanie Spielman Comprehensive Breast Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 7. jul. 2026 · NCT05768139

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Vključevanje udeležencevFaza 1/2
  • Ohio State University, Columbus
Starost 18–90 · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT06710756

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Vključevanje udeležencevFaza 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 12. jun. 2026 · NCT06051695

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Vključevanje udeležencevFaza 1
  • Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 8. jun. 2026 · NCT04890613

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Vključevanje udeležencevFaza 1/2
  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 13. maj 2026 · NCT03686124

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Vključevanje udeležencevFaza 1/2
  • Stefanie Spielman Comprehensive Breast Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 27. mar. 2026 · NCT06395519

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Vključevanje udeležencevFaza 2
  • The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
Starost 18 in več · Ženske · Posodobljeno 23. dec. 2025 · NCT06690775

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Vključevanje udeležencevFaza 1/2
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
Starost 18 in več · Vsi spoli · Posodobljeno 11. dec. 2025 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Vključevanje udeležencevOpazovalna študija
  • Massive Bio SYNERGY-AI site, Columbus
Vse starosti · Vsi spoli · Posodobljeno 28. okt. 2025 · NCT03452774

Študije za Rak jajčnikov v drugih mestih

Druge študije v Columbus

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.